ADRO:NSD-Aduro Biotech, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 3.26

Change

-0.02 (-0.61)%

Market Cap

USD 0.26B

Volume

0.59M

Average Target Price

USD 5.50 (+68.71%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Aduro Biotech, Inc., an immunotherapy company, focuses on the discovery, development, and commercialization of therapies to harness the body's natural immune system for the treatment of patients with challenging diseases. The company is developing ADU-S100, which is in Phase I dose escalation clinical trial and Phase Ib dose escalation clinical trial in combination with spartalizumab to treat patients with advanced, metastatic treatment-refractory solid tumors; Phase I clinical trial in combination with ipilimumab for the treatment of relapsed and refractory melanoma; and Phase II clinical trial in combination with pembrolizumab, an approved anti-PD-1 antibody in patients with squamous cell carcinoma of the head and neck. It is also developing product candidates to prevent or control immune responses through the stimulator of interferon genes pathway. In addition, the company is developing BION-1301, a fully blocking humanized monoclonal anti-APRIL antibody that is in Phase I clinical trial for IgA nephropathy; and CD27, a co-stimulatory receptor, which is in preclinical studies expressed on different immune cells, such as T-lymphocytes and natural killer cells. It has collaboration agreements with Novartis Pharmaceuticals Corporation, Eli Lilly and Company, and Merck Sharp and Dohme B.V.; and license agreements with Karagen Pharmaceuticals, Inc., UC Berkeley, and Memorial Sloan Kettering Cancer Center. The company was formerly known as Oncologic, Inc. and changed its name to Aduro Biotech, Inc. in June 2008. Aduro Biotech, Inc. was founded in 2000 and is headquartered in Berkeley, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-05-28 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

-1.13 (-0.41%)

USD72.21B 46.19 34.50
REGN Regeneron Pharmaceuticals, Inc

+34.20 (+6.29%)

USD61.35B 27.40 20.77
SGEN Seattle Genetics, Inc

-1.42 (-0.93%)

USD26.23B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

+8.28 (+7.80%)

USD25.27B 9.58 8.24
INCY Incyte Corporation

+2.33 (+2.37%)

USD21.35B 47.64 35.20
MRNA Moderna, Inc

+3.36 (+6.44%)

USD20.62B N/A N/A
GMAB Genmab A/S

+1.28 (+4.31%)

USD20.17B 53.85 5.58
BMRN BioMarin Pharmaceutical Inc

-1.10 (-1.03%)

USD19.30B 164.67 98.79
ALNY Alnylam Pharmaceuticals, Inc

-0.25 (-0.19%)

USD15.31B N/A N/A
GLPG Galapagos NV

+3.68 (+1.86%)

USD12.68B 70.13 37.04

ETFs Containing ADRO

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 176.27% 95% A 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 176.27% 95% A 97% A+
Trailing 12 Months  
Capital Gain -5.51% 46% F 56% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -5.51% 46% F 54% F
Trailing 5 Years  
Capital Gain -90.35% 24% F 9% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -90.35% 22% F 8% F
Average Annual (5 Year Horizon)  
Capital Gain -42.01% 6% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -42.01% 6% F 3% F
Risk Return Profile  
Volatility (Standard Deviation) 21.85% 86% B 58% F
Risk Adjusted Return -192.29% 4% F 1% F
Market Capitalization 0.26B 50% F 51% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 4.41 49% F 27% F
Price / Cash Flow Ratio -4.01 42% F 73% C
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -76.04% 45% F 17% F
Return on Invested Capital -82.35% 34% F 11% F
Return on Assets -14.01% 81% B- 25% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 5.90 38% F 22% F
Short Percent 3.99% 59% F 45% F
Beta 0.29 90% A- 86% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector